

**MINUTES**  
**INSTITUTIONAL BIOSAFETY COMMITTEE**  
**DATE: April 10, 2026**

**Attendance:** Total Attending: 11

**Voting Members Present:** 10

**Called to Order:** 10:00 a.m.

<b>Name</b>	<b>Expertise</b>	<b>Present</b>
Linda Cassidy, MS	Non-Voting Member	X
Sue Gotta, MS	rDNA; Select Agents	X
Gerald Grunwald, PhD	rDNA; Biochemistry; Cellular & Developmental Biology	X
Douglas C. Hooper, PhD	rDNA; Immunology; Gene Transfer	X
Botond Igyarto, PhD	Microbiology	X
Loretta Kelly, Esq.	Non-affiliate Community Member	X
Kathleen "Kitty" Kono	Non-Affiliate Community Member	X
Phil LaTourette, DVM	Laboratory Animal Sciences	X
Sara Meyer, PhD	Cancer Biology	X
Fabienne Paumet, PhD	Cellular Biology & Biochemistry	
Drake Stierman	Safety Officer	X
Megan Watson, MS	Lab Specialist	X

**MINUTES REVIEWED:**

Minutes of the March 13, 2026 meeting were presented for review. The minutes were approved with modifications.

Motion to Approve: Phil LaTourette

Seconded: Loretta Kelly

Total = 10; For-10, Opposed-0, Abstained-0

**NEW PROTOCOLS:**

**1. Principal Investigator E.S.**

IBC Control# 26-03-1019

**Summary:**

- This study will investigate the effects on cell growth and tumor formation of various enzyme inhibitors and chemotherapeutic agents, used to treat human-derived breast cancer cell lines with known cell signaling mutations.
- This is an in vivo and in vitro study
- The principal risk identified was:
  - Human cell lines
  - Chemotherapeutics
  - Enzyme Inhibitors
- Containment has been set to BSL-2 and ABSL-2.

**Committee Review:**

- This protocol did not involve either recombinant or synthetic DNA.
- The risks were adequately identified by the Principal Investigator and appropriate mitigation was described in the protocol.
- Clarifications were requested.
- A motion was made and seconded to provisionally approve this protocol. The motion was unanimously approved.

**ADMINISTRATIVELY APPROVED ITEMS:**

The KSI database indicates the following items have been given administrative approval since our last meeting:

**April 10, 2026**

Protocol #	PI - Initials	Form type	Comments
24-03-820	GK	Continuing Review	Active - updated personnel only
24-01-781	AA	Amendment	Added use of Carfilzomib
24-02-811	MS	Continuing Review	Active - updated personnel only
23-04-669-1	AL	Continuing Review	Active - updated personnel only, 3 yr review
24-03-818	GK	Continuing Review	Active - updated personnel only
25-04-945	MS	Amendment	Updated personnel only, clinical trial
23-02-658	JB	Continuing Review	Active - no updates
23-01-634-1	NC	Continuing Review	Active - updated personnel only, 3 yr review
24-07-871	MD	Amendment	Updated attached IB, clinical trial
23-05-680	BI	Amendment	Added Pseudomonas & attached SOP
25-08-973	MD	Amendment	Updated personnel only, clinical trial
22-11-609	KK	Continuing Review	Active - updated Protocol Summary & Waste information
21-04-365-1	JS	Continuing Review	Active - updated personnel only
25-08-973	MD	Amendment	Updated attached IB, clinical trial
22-04-50-1	LL	Continuing Review	Active - updated personnel only
23-11-744	UN	Continuing Review	Active - no updates
22-09-574	AM	Continuing Review	Active - updated personnel & attached training form
22-07-475-1	BB	Continuing Review	Active - no updates, closed to enrollment, clinical trial
21-10-456	MT	Continuing Review	Active - updated personnel only
24-03-824	SW	Continuing Review	Active - no updates
22-12-616	GD	Continuing Review	Active - updated personnel & research location
22-12-620-1	SK	Continuing Review	Active - updated personnel & research location, 3 yr review
23-11-768	A.M.R	Continuing Review	Active - updated personnel only
21-03-359	JH	Continuing Review	Active - updated personnel only
22-03-492-1	QL	Continuing Review	Active - updated personnel only
23-05-680	BI	New	Submittal of previously approved work

**OTHER BUSINESS:**

Sue Gotta updated the committee about the ABL3 and BSL3 projects. The HVAC air handler issues in 651 ABL3 have been resolved with hopes the lab can be running by June. The BSL-3 labs in 352 and 5<sup>th</sup> floor hope to have bubble damper parts installed so labs can be commissioned in July. Exhaust issues in these areas have been repaired. Two labs will be working with SARS-CoV-2, original strain, following BSL-2 and ABSL-2 precautions and procedures. Safety levels will be modified if needed.

Meeting Adjourned: 10:23 a.m.

Respectfully submitted for the IBC,

/s/Gerald Grunwald, PhD  
Chair, Institutional Biosafety Committee

**GG/lc**